SELLAS Life Sciences Group (SLS) in Pivotal Point Check: Prospects for Groundbreaking Survival Data in AML Drive 18% Rally!
Reading Time: 2 minutes
Advanced Cancer Study: The leading drug Galinpepimut-S (GPS) is on the brink of a critical Phase 3 milestone. Management's Confidence: The CEO sees a very good chance of surpassing previous survival data in acute myeloid leukemia. Solid Financial Foundation: 107 million USD in cash secure the upcoming data releases. SELLAS Life Sciences Group, a late-stage US biotechnology company developing novel cancer therapies, attracted investor interest on May 20, 2026. The stock surged approximately 18% on high trading volume. This price jump...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
